Boston Scientific Corp
BSXNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 14/3055% below fair value
$41.98−1.01 (-2.35%)
Close on Nov 20, 2026Market cap $60.84BP/E 17.0Yield –
Boston Scientific Restructuring Charges Incurred by Quarter
Restructuring Charges Incurred ($M) ($M)
Boston Scientific Restructuring Charges Incurred: $63M in Q3 2026, down 887.5% from a year earlier.
Latest, Q3 2026
63
Period ended Sep 30, 2026
Change on a year earlier
-887.5%
-8 in Q3 2025
History
51 quarters
Since Q1 2014
Sources
38
Documents cited below
Where the Q3 2026 figure comes from
Source: Form 10-Q — FY2026Q3 (filed 2026-11-02) ↗
Reported in Form 10-K/10-Q Restructuring Footnote.
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Boston Scientific Restructuring Charges Incurred ($M), quarterly Q1 2014–Q3 2026 [Data set]. Compiled from Boston Scientific SEC filings and investor materials. https://stockdatahq.com/stocks/bsx/kpis/fn-restruct-chg
See every metric in the Boston Scientific KPI table. Data updated Nov 4, 2026.
See a number that looks wrong?